{"id":"ultra-rapid-lispro","safety":{"commonSideEffects":[{"rate":"null","effect":"Hypoglycemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It does this by binding to the insulin receptor on the surface of pancreatic beta cells, triggering a cascade of intracellular signaling events that ultimately lead to insulin release. This results in a rapid increase in blood glucose levels, which helps to lower blood sugar levels in people with diabetes.","oneSentence":"Ultra-Rapid Lispro is a rapid-acting insulin analog that works by stimulating insulin release from the pancreas.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:52:22.040Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT05508061","phase":"NA","title":"Ultrarapid Insulin Administered by a Bihormonal Closed Loop System in Patients With Type 1 Diabetes","status":"COMPLETED","sponsor":"Inreda Diabetic B.V.","startDate":"2022-10-19","conditions":"Type 1 Diabetes","enrollment":12},{"nctId":"NCT06600776","phase":"PHASE4","title":"Mealtime or Post-meal Dosing of URLi in Medtronic 780G Hybrid Closed Loop System","status":"NOT_YET_RECRUITING","sponsor":"Tel-Aviv Sourasky Medical Center","startDate":"2024-10-06","conditions":"Type 1 Diabetes (T1D)","enrollment":50},{"nctId":"NCT02871089","phase":"NA","title":"Closed Loop From Onset in Type 1 Diabetes","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Cambridge","startDate":"2017-01","conditions":"Diabetes Mellitus, Type 1 Diabetes","enrollment":96},{"nctId":"NCT04977908","phase":"NA","title":"Closing the Loop in Adults With Type 1 Diabetes (CLEAR)","status":"COMPLETED","sponsor":"University of Cambridge","startDate":"2021-08-31","conditions":"Type 1 Diabetes","enrollment":26},{"nctId":"NCT05660941","phase":"NA","title":"Automated Fully Closed-Loop Insulin Delivery in Type 1 Diabetes With Ultra-Rapid Lispro (ACOLYTE Study)","status":"UNKNOWN","sponsor":"Manchester University NHS Foundation Trust","startDate":"2023-07-21","conditions":"Diabetes Mellitus, Type 1","enrollment":26},{"nctId":"NCT05257460","phase":"NA","title":"Closing the Loop in Adults With Type 1 Diabetes Under Free Living Conditions (AP@Home04_Phase 4)","status":"COMPLETED","sponsor":"University of Cambridge","startDate":"2022-01-25","conditions":"Type 1 Diabetes","enrollment":28},{"nctId":"NCT03952130","phase":"PHASE3","title":"A Study of LY900014 Compared to Insulin Lispro (Humalog) in Adults With Type 1 Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2019-05-29","conditions":"Type 1 Diabetes Mellitus","enrollment":354},{"nctId":"NCT03952143","phase":"PHASE3","title":"A Study of LY900014 Compared to Insulin Lispro (Humalog) in Adults With Type 2 Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2019-05-27","conditions":"Type 2 Diabetes Mellitus","enrollment":628},{"nctId":"NCT03740919","phase":"PHASE3","title":"A Study Comparing LY900014 to Insulin Lispro (Humalog) in Children and Adolescents With Type 1 Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2019-04-07","conditions":"Type 1 Diabetes Mellitus","enrollment":751},{"nctId":"NCT04049123","phase":"PHASE1","title":"A Study of LY900014 in Healthy Chinese Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2019-11-18","conditions":"Healthy","enrollment":15},{"nctId":"NCT03830281","phase":"PHASE3","title":"A Study Comparing LY900014 to Insulin Lispro (Humalog) in Adults With Type 1 Diabetes Using Insulin Pump Therapy","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2019-02-14","conditions":"Type 1 Diabetes Mellitus","enrollment":471},{"nctId":"NCT03760640","phase":"PHASE2","title":"A Study of LY900014 in a Medtronic Pump","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2019-02-18","conditions":"Type1 Diabetes Mellitus","enrollment":42},{"nctId":"NCT02206568","phase":"PHASE1","title":"Pharmacokinetics of Ultra-Rapid-Acting Insulin Lispro (URAL) in Type 1 Diabetes Mellitus","status":"WITHDRAWN","sponsor":"Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.","startDate":"2014-06","conditions":"Type 1 Diabetes Mellitus","enrollment":""},{"nctId":"NCT03465878","phase":"PHASE1","title":"A Study of LY900014 in Participants With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2018-03-26","conditions":"Type 1 Diabetes Mellitus","enrollment":56},{"nctId":"NCT02703337","phase":"PHASE1","title":"A Study of LY900014 in Participants With Type 2 Diabetes on Insulin Injection Therapy","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2016-03","conditions":"Diabetes Mellitus, Type 2","enrollment":30},{"nctId":"NCT02703324","phase":"PHASE1","title":"A Study of LY900014 Formulation in Participants With Type 1 Diabetes Mellitus Using Insulin Pumps","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2016-03","conditions":"Diabetes Mellitus, Type 1","enrollment":30},{"nctId":"NCT02703350","phase":"PHASE1","title":"A Study of LY900014 in Participants With Type 1 Diabetes on Insulin Injection Therapy","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2016-03","conditions":"Diabetes Mellitus, Type 1","enrollment":30},{"nctId":"NCT03341312","phase":"PHASE1","title":"A Comparative Study of LY900014 With Insulin Lispro (Humalog) in Participants With Type 2 Diabetes Mellitus (T2DM)","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2017-11-13","conditions":"Diabetes Mellitus, Type 2","enrollment":36},{"nctId":"NCT02770521","phase":"PHASE1","title":"A Study of Treprostinil and a New Formulation of LY900014 in Healthy Japanese Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2016-05","conditions":"Healthy","enrollment":23},{"nctId":"NCT03305822","phase":"PHASE1","title":"A Study of LY900014 in Participants With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2017-10-11","conditions":"Diabetes Mellitus, Type 2","enrollment":38},{"nctId":"NCT02525744","phase":"PHASE1","title":"A Study of a New LY900014 Formulation in Healthy Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2015-08","conditions":"Healthy","enrollment":24},{"nctId":"NCT03341299","phase":"PHASE1","title":"A Comparative Study of LY900014 With Insulin Lispro (Humalog) in Participants With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2017-11-13","conditions":"Diabetes Mellitus, Type 1","enrollment":36},{"nctId":"NCT02636361","phase":"PHASE1","title":"A Study of Various Formulations of LY900014 in Healthy Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2015-12","conditions":"Healthy","enrollment":26},{"nctId":"NCT02317575","phase":"PHASE1","title":"A Study of LY900014 Formulations in Healthy Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2015-01","conditions":"Healthy Volunteers","enrollment":29},{"nctId":"NCT02752087","phase":"PHASE1","title":"A Study to Compare the Effects of a Test and Reference Formulation of LY900014 in Healthy Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2016-04","conditions":"Healthy","enrollment":24},{"nctId":"NCT03334448","phase":"PHASE1","title":"A Study to Compare 2 Formulations of LY900014 in Healthy Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2017-12-04","conditions":"Healthy","enrollment":49},{"nctId":"NCT03056456","phase":"PHASE1","title":"A Study of LY900014 Administered in Participants With Type 1 Diabetes Using an Insulin Pump","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2017-02-23","conditions":"Diabetes Mellitus, Type 1","enrollment":24},{"nctId":"NCT03407118","phase":"PHASE1","title":"A Study of LY900014 in Japanese Participants With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2018-02-17","conditions":"Diabetes Mellitus, Type 1","enrollment":31},{"nctId":"NCT03286751","phase":"PHASE1","title":"A Comparative Study of LY900014 to Insulin Lispro (Humalog) in Healthy Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2017-10-13","conditions":"Diabetes Mellitus, Type 2","enrollment":42},{"nctId":"NCT03214367","phase":"PHASE3","title":"A Study of LY900014 in Participants With Type 1 Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2017-07-17","conditions":"Type 1 Diabetes Mellitus","enrollment":1392},{"nctId":"NCT03449433","phase":"PHASE1","title":"A Meal Test Study of LY900014 in Participants With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2018-03-15","conditions":"Diabetes Mellitus, Type 1","enrollment":80},{"nctId":"NCT03616977","phase":"PHASE1","title":"Study to Compare 2 Formulations of LY900014 in Healthy Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2018-08-03","conditions":"Healthy","enrollment":69},{"nctId":"NCT03166124","phase":"PHASE1","title":"A Study of LY900014 in Elderly and Younger Adult Participants With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2017-05-24","conditions":"Diabetes Mellitus, Type 1","enrollment":80},{"nctId":"NCT03232983","phase":"PHASE1","title":"A Study of LY900014 Formulation at Different Injection Sites in Healthy Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2017-08-14","conditions":"Diabetes Mellitus, Type 2","enrollment":28},{"nctId":"NCT02942654","phase":"PHASE1","title":"A Study of LY900014 Formulation in Healthy Participants","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2016-11","conditions":"Healthy","enrollment":32},{"nctId":"NCT03214380","phase":"PHASE3","title":"A Study of LY900014 Compared to Insulin Lispro in Participants With Type 2 Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2017-07-14","conditions":"Type 2 Diabetes Mellitus","enrollment":933},{"nctId":"NCT03433677","phase":"PHASE3","title":"A Study of LY900014 and Insulin Lispro With an External Continuous Subcutaneous Insulin Infusion System in Adult Participants With Type 1 Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2018-02-21","conditions":"Diabetes Type 1","enrollment":49},{"nctId":"NCT01000922","phase":"PHASE2","title":"A Study Comparing the Pharmacodynamic Properties of Insulin VIAJECT™, Regular Human Insulin, and Insulin Lispro","status":"COMPLETED","sponsor":"Biodel","startDate":"2006-06","conditions":"Diabetes Mellitus","enrollment":24},{"nctId":"NCT01686620","phase":"PHASE2","title":"A Study Evaluating Safety and Efficacy of BIOD-123 Compared to Insulin Lispro (Humalog®)","status":"COMPLETED","sponsor":"Biodel","startDate":"2012-08","conditions":"Type 1 Diabetes Mellitus","enrollment":132}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["LY900014","Insulin lispro"],"phase":"phase_3","status":"active","brandName":"Ultra-Rapid Lispro","genericName":"Ultra-Rapid Lispro","companyName":"Eli Lilly and Company","companyId":"eli-lilly-and-company","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ultra-Rapid Lispro is a rapid-acting insulin analog that works by stimulating insulin release from the pancreas. Used for Treatment of diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}